- Company
- Drug industry back on full alert as COVID-19 cases resurge
- by Aug 21, 2020 06:26am
- The pharmaceutical industry is on full alert again as the confirmed cases of novel coronavirus infection (COVID-19) is resurging rapidly around Seoul metropolitan area. Some companies have already reinitiated emergency working system with employees working in shifts or from home. The South Korean government has recently decided to toughen th
- Policy
- Promote legislation to include the shingles vaccine in NIP
- by Lee, Jeong-Hwan Aug 21, 2020 06:26am
- A bill is being promoted to include the shingles vaccine, which is classified as a premium vaccine, in the National Immunization Program,(NIP). On the 19th, Yoo Sang-beom, a member of the United Future Party announced that it had proposed a bill with the same content. He explained that the onset of shingles markedly lowers the quality
- Opinion
- [Reporter’s Note] Clinical trial info, do we have enough?
- by Lee, Tak-Sun Aug 21, 2020 06:26am
- South Korea’s Ministry of Food and Drug Safety (MFDS) has decided to provide wider scope of information regarding clinical trial approval process from October last year. And the ministry has been uploading elaborative details about the process on its official website. MFDS explained further disclosure of the information aims to expand treat
- Policy
- Global companies expand business in expensive orphan drugs
- by Lee, Tak-Sun Aug 20, 2020 06:24am
- As global pharmaceutical companies are on to expanding businesses in drugs for rare diseases, the companies are now winning item approvals in South Korean markets. Rare diseases have limited patient size and insufficient treatment options, but the drugs are expensive enough for the companies to seek for profit. On Aug. 19, Ministry of Fo
- Company
- Companies are worried about a sharp decline in Rx drug sales
- by Chon, Seung-Hyun Aug 20, 2020 06:24am
- Pharmaceutical companies are again tense with COVID-19. The prescription drug market suffered a temporary sluggishness due to the aftermath of COVID-19, and while it is recovering, the market has contracted again and is worried. Business activities can be greatly affected by the spread of telecommuting. According to UBIST on the 19th, the tot
- Policy
- Drug Approval system under direct control of the MFDS
- by Lee, Tak-Sun Aug 20, 2020 06:23am
- Drug Approval System, which was in charge of the National Institute of Food and Drug Safety Evaluation, will be carried out at the headquarters of the MFDS. The 'Convergence Innovation Product Support Group', a temporary organization that has been in charge of licensing affairs since last year, is formally incorporated into a department under t
- Policy
- Kwang Dong is continuing the business of Pomalyst
- by Lee, Tak-Sun Aug 20, 2020 06:23am
- Kwang Dong is continuing the business of specializing anticancer drug first generics by challenging the patent for Celgene's multiple myeloma treatment 'Pomalyst' (Pomalidomide). Recently, Kwang Dong is showing a prominence in the anticancer drug business by introducing the first generic drug for multiple myeloma treatment, Revlimid and b
- Opinion
- [Reporter’s Note] Playing the fair game of NHI coverage
- by Kim, Jin-Gu Aug 20, 2020 06:23am
- In a sports game, a referee takes over the game from time to time. When the set rules are not applied fairly, the players would naturally dispute over the biased refereeing. Such is the case for South Korea’s Ministry of Health and Welfare (MOHW) regarding the National Health Insurance (NHI). Recently, MOHW convened a general meeting fo
- Policy
- Chong Kun Dang recruits consignment companies for Atozet
- by Lee, Tak-Sun Aug 19, 2020 06:28am
- Chong Kun Dang submitted an application for approval in April for Atorvastatin-Ezetimibe, generic for Atozet and recruiting consignment companies is also gaining popularity. Chong Kun Dang applied for item approval of Atorvastatin-Ezetimibe through its own clinical trial. Considering the maximum period of 6 months for the approval review p
- Company
- Big 5 except Severance clear Novartis’ Kisqali prescription
- by Eo, Yun-Ho Aug 19, 2020 06:28am
- South Korean general hospitals are ready to prescribe a third cyclin-dependent kinase (CDK) 4/6 inhibitor Kisqali approved after Ibrance and Verzenio. According to the related industry sources, Novartis’ Kisqali (ribocilib) has passed drug committees (DC) at all Big Five general hospitals&8212;Samsung Medical Center, Seoul National Uni
